Why Biogen's Q4 Results Were a Bust
You can almost always know how strong a company's near-term prospects are by looking at its stock price. Biogen's (NASDAQ: BIIB) shares sank more than 17% last year while the overall market soared, reflecting significant investor pessimism. However, the stock is up solidly so far in 2021. That's a good sign that investors' confidence has increased.
But that optimism could take a hit after Biogen reported its fourth-quarter results before the market opened on Wednesday. Here are the highlights from the biotech's Q4 update.
Image source: Getty Images.
Source Fool.com
